OR WAIT null SECS
December 05, 2018
AbbVie will grant Pfizer license to launch a biosimilar to AbbVie’s Humira worldwide.
November 08, 2018
AbbVie will grant Momenta license to launch a biosimilar to AbbVie’s Humira.
October 12, 2018
Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab).
October 11, 2018
Biotechnology developers should be aware of subtle differences between the way that European and United States patent authorities approach monoclonal antibodies.
July 27, 2018
The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development.
Waters’ acquisition of Prosolia’s DESI technology boosts its mass spectrometry imaging portfolio.
July 18, 2018
AbbVie will grant Mylan license to launch a biosimilar to AbbVie’s Humira.
April 06, 2018
Shashank Upadhye, Esq., managing partner at Amin Talati Upadhye, will discuss intellectual property/patent issues for active pharmaceutical ingredients and abbreviated new drug applications at CPhI North America in Philadelphia, PA, on Tuesday, April 24, 2018.
March 22, 2018
Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.
March 19, 2018
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.